These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7496836)

  • 1. Proliferative indices and oncoprotein expression in benign and malignant breast biopsies.
    Brower ST; Tartter PI; Ahmed S; Brusco CM; Bossolt K; Hayden C; Bleiweiss I
    Ann Surg Oncol; 1995 Sep; 2(5):416-23. PubMed ID: 7496836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.
    Brower ST; Ahmed S; Tartter PI; Bleiweiss I; Amberson JB
    Ann Surg Oncol; 1995 Sep; 2(5):440-4. PubMed ID: 7496840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Her-2/neu oncogene protein product and epidermal growth factor receptors in surgical specimens of human breast cancers.
    Moe RE; Moe KS; Porter P; Gown AM; Ellis G; Tapper D
    Am J Surg; 1991 May; 161(5):580-3. PubMed ID: 1674411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA ploidy, cell kinetics, and epidermal growth factor receptor and HER2/neu oncoprotein expression in primary operable breast cancer.
    d'Agnano I; Bucci B; Mottolese M; Benevolo M; Conti L; Botti C; Vecchione A; Casillo S; Zupi G
    Ann N Y Acad Sci; 1996 Apr; 784():472-81. PubMed ID: 8651601
    [No Abstract]   [Full Text] [Related]  

  • 5. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma.
    Lee AK; Wiley B; Loda M; Bosari S; Dugan JM; Hamilton W; Heatley GJ; Cook L; Silverman ML
    Mod Pathol; 1992 Jan; 5(1):61-7. PubMed ID: 1347424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell proliferation, nuclear ploidy, and EGFr and HER2/neu tyrosine kinase oncoproteins in infiltrating ductal breast carcinoma.
    Fernández Val JF; Losada J; Arregui Murua MA; Sarría R
    Cancer Genet Cytogenet; 2002 Oct; 138(1):69-72. PubMed ID: 12419588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Her-2/neu oncogene expression in Puerto Rican females with breast cancer.
    Peredo R; Sastre G; Serrano J; Hunter Mellado R
    Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1025-32. PubMed ID: 11785652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.
    Baak JP; Chin D; van Diest PJ; Ortiz R; Matze-Cok P; Bacus SS
    Lab Invest; 1991 Feb; 64(2):215-23. PubMed ID: 1671789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of different methods for determination of proliferative activity of breast carcinomas].
    Mink D; Villena-Heinsen C; Tossounidis I; Schmidt W
    Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():53-6. PubMed ID: 8672927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Her-2/neu, Ki-67 expression and ploidy in breast carcinoma].
    Lukashina MI; Glukhova EI; Zhukova LG; Ermilova VD; Bogatyrev VN; Baryshnikov AIu
    Arkh Patol; 2003; 65(5):25-9. PubMed ID: 14664144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
    Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.
    Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U
    Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.
    Gasparini G; Gullick WJ; Bevilacqua P; Sainsbury JR; Meli S; Boracchi P; Testolin A; La Malfa G; Pozza F
    J Clin Oncol; 1992 May; 10(5):686-95. PubMed ID: 1349034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer.
    Stark A; Hulka BS; Joens S; Novotny D; Thor AD; Wold LE; Schell MJ; Melton LJ; Liu ET; Conway K
    J Clin Oncol; 2000 Jan; 18(2):267-74. PubMed ID: 10637239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary study on oncogene product immunohistochemistry (c-erbB-2, c-myc, ras p21, EGFR) in breast pathology.
    Saccani Jotti G; Fontanesi M; Bombardieri E; Gabrielli M; Veronesi P; Bianchi M; Becchi G; Bogni A; Tardini A
    Int J Biol Markers; 1992; 7(1):35-42. PubMed ID: 1349907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer.
    Pinto AE; André S; Laranjeira C; Soares J
    Pathology; 2005 Feb; 37(1):45-50. PubMed ID: 15875733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
    Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
    Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 mutations in benign breast tissue.
    Millikan R; Hulka B; Thor A; Zhang Y; Edgerton S; Zhang X; Pei H; He M; Wold L; Melton LJ
    J Clin Oncol; 1995 Sep; 13(9):2293-300. PubMed ID: 7666086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of the epidermal growth factor-receptor to the growth fraction (Ki-67 antibody) and the flow cytometric S-phase as cell kinetics parameters, in human mammary carcinomas.
    Gasparini G; Reitano M; Bevilacqua P; Meli S; Pozza F; Santini G
    Anticancer Res; 1991; 11(4):1597-603. PubMed ID: 1746917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.